Axonics, Inc. (NASDAQ:AXNX) Shares Bought by Slotnik Capital LLC

Slotnik Capital LLC increased its holdings in Axonics, Inc. (NASDAQ:AXNX) by 11.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 99,784 shares of the company’s stock after buying an additional 10,000 shares during the period. Axonics comprises approximately 3.3% of Slotnik Capital LLC’s holdings, making the stock its 11th biggest position. Slotnik Capital LLC owned 0.20% of Axonics worth $6,708,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Xponance Inc. increased its position in Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after buying an additional 225 shares during the period. Headlands Technologies LLC increased its holdings in shares of Axonics by 31.1% in the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after acquiring an additional 265 shares during the period. Arizona State Retirement System lifted its position in Axonics by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock valued at $960,000 after purchasing an additional 355 shares during the last quarter. Scholtz & Company LLC boosted its stake in Axonics by 7.8% during the 4th quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock valued at $310,000 after purchasing an additional 360 shares during the period. Finally, Whittier Trust Co. grew its position in Axonics by 59.1% in the 1st quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after purchasing an additional 424 shares during the last quarter. Institutional investors own 99.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $69.57.

Axonics Price Performance

Shares of NASDAQ:AXNX opened at $69.01 on Tuesday. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -215.66 and a beta of 0.81. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $69.68. The stock’s 50 day moving average price is $68.69 and its 200 day moving average price is $67.96.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. During the same quarter in the previous year, the business earned ($0.15) EPS. The company’s quarterly revenue was up 23.3% compared to the same quarter last year. On average, sell-side analysts expect that Axonics, Inc. will post 0.24 EPS for the current year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.